Peptides DB
Research-centric peptide and protocol reference hub

Exenatide record · updated 6h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 20 studiesJump to the evidenceCompare
What is Exenatide used for?

Exenatide is a synthetic peptide that mimics the action of glucagon-like peptide-1 (GLP-1), a hormone involved in glucose metabolism. It functions primarily as a GLP-1 receptor agonist, promoting insulin secretion in response to elevated blood glucose levels, inhibiting glucagon release, and slowing gastric emptying. These mechanisms contribute to improved glycemic control in patients with type 2 diabetes and may also aid in weight management due to its appetite-suppressing effects.

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Exenatide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 125 registered trials. It describes the research record, not a recommendation.

Identity
NameExenatide
Chain length—
Molecular weight4,187 Da
FormulaC184H282N50O60S
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 45588096. No verified residue count for this compound.

Pharmacology
MechanismGLP-1 receptor agonist
RouteSubcutaneous injection
Half-life~2.4 hours
Time to peak2 hours
Duration~10 hours
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 19, 2026. How this works →
Research stats
Total studies20
Human / animal / cellular6 / 2 / 0
Highest trial phasePhase 3
Years covered2023–2026
Latest study8d ago
Publication history
20232026
Research funding
618 NIH projects · $22.2M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports6,539
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

20 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.
FindingaSR: 0.85; 95% CI: 0.76-0.94 for antidepressants initiation
Human2026Full text read0.80
Development of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction.
FindingDrug loading up to 4.7% w/w.
Animal2026Full text read0.70
Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.
Finding53.1% of skin and injection-site reports for exenatide.
review2026Full text read0.90
Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.
FindingAll doses of semaglutide fully prevented drug- and stress-induced reinstatement of fentanyl seeking.
Animal2026Full text read0.70
GLP-1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri-Procedural Guidance.
FindingAspiration rates during colonoscopy are approximately 0.01%-0.05%.
review2026Full text read0.80
Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study.
FindingExenatide showed an inverse association in FAERS (ROR, 0.60; 95% CI, 0.46 to 0.77).
Human2026Full text read0.90
Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.
Finding243,114 GLP-1 primary-suspect case-product records within 8,995,547 background reports.
—2026Full text read0.80
Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
Finding544 PT-class pairs met the ≥3-of-4 signal criterion.
Human2026Full text read0.90
GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles.
FindingExenatide 20 µg SC was associated with a reduction in systolic blood pressure of -6.64 mmHg, 95% CI -13.22 to -0.17.
review2026Full text read0.80
Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.
FindingNot reported in abstract.
review2023Full text read0.80
Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes.
FindingHR, 0.81 [95% CI, 0.70-0.93] for reduced risk of death with semaglutide compared to dulaglutide.
Human2026Full text read0.80
Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in adults with type 2 diabetes and established atherosclerotic cardiovascular disease: systematic review and meta-analysis of randomised trials.
Finding11% reduction in major adverse cardiovascular events (hazard ratio: 0.89, 95% CI: 0.83-0.96)
review2025Full text read0.90

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Exenatide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Exenatide is discussed should be drawn from it.